GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2010

EU Approves Roche’s Xeloda Combined with Oxaliplatin for Post-Surgical Colon Cancer Therapy

  • Roche confirmed European approval of Xeloda (capecitabine) as combination therapy with oxaliplatin for the post-surgical treatment of patients with early colon cancer. Approval is based on results from the pivotal NO16968 trial. Label extensions covering the Xeloada-oxaliplatin combination (commonly known as XELOX), are also expected in other territories Roche stated. Xeloda monotherapy is already approved in Europe, the U.S. and Japan and elsewhere, for the immediate post-surgical treatment of colon cancer patients.

    First licensed in 2001, Xeloda is now available in over 100 countries as either monotherapy or combination therapy for the treatment of colorectal cancer, gastric cancer, and metastatic breast cancer.

    The drug made sales of CHF1.26 billion ($1.18 billion) in 2009, up 7% on sales in 2008.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?